-+ 0.00%
-+ 0.00%
-+ 0.00%

Precision Biosciences Advances Gene Therapy Pipeline With Ongoing Phase 1/2a ELIMINATE‑B Trial For PBGENE‑HBV And Anticipated Q1 2026 IND Clearance For PBGENE‑DMD; Data Updates Expected Throughout 2026

Benzinga·01/12/2026 12:19:35
Listen to the news

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026

PBGENE-DMD expecting IND clearance in Q1 2026 for Phase 1/2 FUNCTION-DMD study with initial data from multiple patients expected in 2026

Unaudited cash, cash equivalents, and restricted cash of approximately $137 million as of December 31, 2025, anticipated to fund PBGENE-HBV and PBGENE-DMD data milestones through 2028

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today provided a business update and announced strategic priorities for 2026, highlighting recent progress for its two lead programs, upcoming clinical milestones, and a strong financial position supporting execution through key value-inflection points.